Literature DB >> 26221228

The tumor protection effect of high-frequency administration of whole tumor cell vaccine and enhanced efficacy by the protein component from Agrocybe aegerita.

Yi Liang1, Hui Sun2.   

Abstract

Whole tumor cell vaccines have been widely studied and elicits limited immune responses because of the poor immunogenicity. In the present study, we discovered that high-frequency administration of irradiated whole tumor cell vaccine triggered rejection of tumor cells (90% or 100% of the mice that were vaccinated with irradiated H22 cells or S180 respectively were protected), and provided cross-protection and long-term anti-tumor immunity in BALB/c mouse models. The antitumor activity required CD4+, CD8+ T cells and macrophage that was proved in the nude mice and cell depletion mouse models. The adoptive transfer experiment suggested that repeated whole tumor cell vaccination successfully stimulated the anti-tumor response by activation of the immune cells. A high immunization frequency within a short period of time and the presence of glycosylated molecules and nucleic acids on the surface of intact tumor cells were crucial for the successful prevention of tumor growth by whole tumor cell vaccines. Moreover, Yt, the protein component from fungus Agrocybe aegerita, increased whole tumor cell vaccine-mediated tumor rejection and cross-protection effect. These data indicated that the frequency of administration of whole tumor cell vaccines was of critical importance for the efficacy, which needed to be integrated into vaccine strategies for producing potential vaccines.

Entities:  

Keywords:  High-frequency; immunodeficient mice; protein component; whole tumor cell vaccine

Year:  2015        PMID: 26221228      PMCID: PMC4509173     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  31 in total

Review 1.  Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma.

Authors:  Jon Arnason; David Avigan
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

2.  Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.

Authors:  Qiushan He; Jinlong Li; Weihua Yin; Zhichun Song; Zhen Zhang; Tienan Yi; Jia Tang; Demin Wu; Yue Lu; Zhen Wang; Dan Liu; Xiaoren Zhang; Zhiming Hu; Jimin Gao
Journal:  Cancer Immunol Immunother       Date:  2011-02-18       Impact factor: 6.968

3.  Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.

Authors:  Dan Laheru; Barbara Biedrzycki; Elizabeth M Jaffee
Journal:  Methods Mol Biol       Date:  2013

Review 4.  GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.

Authors:  James E Ward; Douglas G McNeel
Journal:  Expert Opin Biol Ther       Date:  2007-12       Impact factor: 4.388

Review 5.  Cell based cancer vaccines: regulatory and commercial development.

Authors:  John Copier; Stephen Ward; Angus Dalgleish
Journal:  Vaccine       Date:  2007-09-27       Impact factor: 3.641

6.  Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.

Authors:  M Janke; B Peeters; O de Leeuw; R Moorman; A Arnold; P Fournier; V Schirrmacher
Journal:  Gene Ther       Date:  2007-10-04       Impact factor: 5.250

7.  Experimental study of specific immunotherapy induced by H22 autologous tumor as whole tumor cell vaccine.

Authors:  Wei Yang; Cheng Guo; Qing-guang Liu; Chengen Pan
Journal:  Biomed Pharmacother       Date:  2008-09-18       Impact factor: 6.529

8.  Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

Authors:  Ute E Burkhardt; Ursula Hainz; Kristen Stevenson; Natalie R Goldstein; Mildred Pasek; Masayasu Naito; Di Wu; Vincent T Ho; Anselmo Alonso; Naa Norkor Hammond; Jessica Wong; Quinlan L Sievers; Ana Brusic; Sean M McDonough; Wanyong Zeng; Ann Perrin; Jennifer R Brown; Christine M Canning; John Koreth; Corey Cutler; Philippe Armand; Donna Neuberg; Jeng-Shin Lee; Joseph H Antin; Richard C Mulligan; Tetsuro Sasada; Jerome Ritz; Robert J Soiffer; Glenn Dranoff; Edwin P Alyea; Catherine J Wu
Journal:  J Clin Invest       Date:  2013-08-05       Impact factor: 14.808

9.  An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.

Authors:  F Pericle; M Giovarelli; M P Colombo; G Ferrari; P Musiani; A Modesti; F Cavallo; F Di Pierro; F Novelli; G Forni
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

10.  Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity.

Authors:  L Chen; P McGowan; S Ashe; J Johnston; Y Li; I Hellström; K E Hellström
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

View more
  2 in total

1.  Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor.

Authors:  Flavia Fontana; Manlio Fusciello; Christianne Groeneveldt; Cristian Capasso; Jacopo Chiaro; Sara Feola; Zehua Liu; Ermei M Mäkilä; Jarno J Salonen; Jouni T Hirvonen; Vincenzo Cerullo; Hélder A Santos
Journal:  ACS Nano       Date:  2019-05-17       Impact factor: 15.881

2.  In vivo antitumor activity evaluation of cancer vaccines prepared by various antigen forms in a murine hepatocellular carcinoma model.

Authors:  Chunfeng Si; Maolei Xu; Meiyu Lu; Yan Yu; Meizi Yang; Miaomiao Yan; Ling Zhou; Xiaoping Yang
Journal:  Oncol Lett       Date:  2017-10-11       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.